Vaccine Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Finance
RiVax maker reports improved net loss in Q2
September 14th, 2005
DOR BioPharma, Inc., (DOR), a biopharmaceutical company focused on the development of therapeutics and vaccines for unmet medical needs, announced its financial results for the second quarter ended June 30, 2005. The company reported an improved net loss to shareholders of $541,412 or $0.01 per share for the second quarter of 2005, compared to $1,473,376 or $0.04 per share for the second quarter of 2004. Revenues attributable to grants for the second quarter of 2005 were $1,422,703, compared to $0 in the second quarter of 2004. Research and development costs for the second quarter of 2005 were $736,905 compared to $990,013 for the second quarter of 2004. General and...
Source: Vaccine Weekly (2005-09-14)
|
